On Nov 19, major Wall Street analysts update their ratings for $Aclaris Therapeutics (ACRS.US)$, with price targets ranging from $3 to $13.
Jefferies analyst Roger Song upgrades to a buy rating, and adjusts the target price from $1 to $7.
Stifel analyst Alex Thompson CFA maintains with a hold rating, and maintains the target price at $3.
BTIG analyst Julian Harrison upgrades to a buy rating, and sets the target price at $8.
Piper Sandler analyst Christopher Raymond upgrades to a buy rating, and adjusts the target price from $2 to $13.
Leerink Partners analyst Thomas Smith upgrades to a buy rating, and adjusts the target price from $2 to $7.
Furthermore, according to the comprehensive report, the opinions of $Aclaris Therapeutics (ACRS.US)$'s main analysts recently are as follows:
BSI-045B, being the first anti-TSLP demonstrating clinical proof of concept in atopic dermatitis, is considered to be underpinned by a distinct binding profile. Further development in a placebo-controlled study is supported for additional substantiation in atopic dermatitis and potentially other areas. Should these studies prove successful, BSI-045B could emerge as a pioneer in the congested atopic dermatitis market with a unique mechanism of action that potentially improves both efficacy and safety.
Aclaris Therapeutics has taken a significant step by acquiring the complete ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb. This acquisition is highlighted by the remarkable potency of BSI-045B, which has demonstrated up to 71-times greater efficacy versus tezepelumab, and up to nine times higher potency compared to other anti-TSLP therapies currently under development. Impressively, early Phase 2a open-label data suggests that BSI-045B could become a preferred early-line treatment for atopic dermatitis.
Here are the latest investment ratings and price targets for $Aclaris Therapeutics (ACRS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月19日，多家華爾街大行更新了$Aclaris Therapeutics (ACRS.US)$的評級，目標價介於3美元至13美元。
富瑞集團分析師Roger Song上調至買入評級，並將目標價從1美元上調至7美元。
斯迪富分析師Alex Thompson CFA維持持有評級，維持目標價3美元。
BTIG分析師Julian Harrison上調至買入評級，目標價8美元。
派傑投資分析師Christopher Raymond上調至買入評級，並將目標價從2美元上調至13美元。
Leerink Partners分析師Thomas Smith上調至買入評級，並將目標價從2美元上調至7美元。
此外，綜合報道，$Aclaris Therapeutics (ACRS.US)$近期主要分析師觀點如下：
BSI-450億，作爲首個抗TSLP在特應性皮炎中展示臨床概念的藥物，被認爲具備獨特的結合特性。在安慰劑對照研究中進一步發展的支持下，預計將在特應性皮炎及其他領域獲得額外驗證。如果這些研究成功，BSI-450億有可能成爲擁擠的特應性皮炎市場中的先鋒，具有獨特的作用機制，有可能同時改善療效和安全性。
aclaris therapeutics通過收購抗TSLP人源化單克隆抗體及抗TSLP/IL4R雙特異性單克隆抗體在中國以外的完整權利，邁出了重要一步。這項收購的亮點是BSI-450億的顯著效力，其相較於tezepelumab的療效高達71倍，相較於其他目前仍在開發中的抗TSLP療法的效能高出近九倍。值得注意的是，早期的第二階段開放標籤數據表明，BSI-450億可能成爲特應性皮炎的首選早期治療方法。
以下爲今日5位分析師對$Aclaris Therapeutics (ACRS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
